Standout Papers

Development of the Proteasome Inhibitor Velcade™ (Bortezomib) 2004 2026 2011 2018 558
  1. Development of the Proteasome Inhibitor Velcade™ (Bortezomib) (2004)
    Julian Adams, Michael Kauffman Cancer Investigation
  2. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma (2004)
    Sundar Jagannath, Bart Barlogie et al. British Journal of Haematology

Immediate Impact

16 by Nobel laureates 28 from Science/Nature 55 standout
Sub-graph 1 of 23

Citing Papers

Evolutionary-scale prediction of atomic-level protein structure with a language model
2023 StandoutScience
Z-nucleic-acid sensing triggers ZBP1-dependent necroptosis and inflammation
2020 StandoutNature
1 intermediate paper

Works of Michael Kauffman being referenced

KPT‐330 inhibitor of CRM1 (XPO1)‐mediated nuclear export has selective anti‐leukaemic activity in preclinical models of T‐cell acute lymphoblastic leukaemia and acute myeloid leukaemia
2013
An Integrated in Silico 3D Model-Driven Discovery of a Novel, Potent, and Selective Amidosulfonamide 5-HT1A Agonist (PRX-00023) for the Treatment of Anxiety and Depression
2006

Author Peers

Author Last Decade Papers Cites
Michael Kauffman 4225 1737 1705 188 5.5k
Sharon Shacham 4339 1370 1308 220 5.7k
Hiroshi Yasui 3002 1312 1496 139 4.7k
Warren Fiskus 5077 1178 1679 136 6.2k
Kimberly Stegmaier 3533 1009 1206 132 5.2k
Alwin Krämer 3941 2106 818 125 5.8k
Masaharu Akiyama 3125 1268 1692 90 5.0k
Mohamed Rahmani 3903 1341 1190 95 5.6k
Raymond Taetle 2176 1236 1029 128 4.4k
Joel Johansson 4721 1905 1168 101 6.4k
Jérôme Moreaux 2862 1442 1924 167 4.7k

All Works

Loading papers...

Rankless by CCL
2026